Cargando…

Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival

Glioblastoma (GBM) can be classified into molecular subgroups, on the basis of biomarker expression. Here, we classified our cohort of 163 adult GBMs into molecular subgroups according to the expression of proteins encoded by genes of alpha thalassemia/mental retardation syndrome X-linked (ATRX), is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaurasia, Ajay, Park, Sung-Hye, Seo, Jeong-Wook, Park, Chul-Kee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951549/ https://www.ncbi.nlm.nih.gov/pubmed/27478330 http://dx.doi.org/10.3346/jkms.2016.31.8.1208

Ejemplares similares

Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients
por: Priambada, Dody, et al.
Publicado: (2023)

Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1(R132H) mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss
por: Cai, Hong-Qing, et al.
Publicado: (2018)

TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors
por: Cantero, Diana, et al.
Publicado: (2020)

Correlation of immunohistochemical expression of HIF-1alpha and IDH1 with clinicopathological and therapeutic data of moroccan glioblastoma and survival analysis
por: Sfifou, Fatima, et al.
Publicado: (2021)

ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma
por: Babikir, Husam, et al.
Publicado: (2021)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients
por: Cho, Hye Rim, et al.
Publicado: (2017)

Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: application of DSC perfusion MR imaging
por: Cho, Hye Rim, et al.
Publicado: (2016)

Immunohistochemical Classification of Primary and Secondary Glioblastomas
por: Lee, Kyu Sang, et al.
Publicado: (2013)

IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma Patients
por: Stancheva, Gergana, et al.
Publicado: (2014)

ATRX immunostaining predicts IDH and H3F3A status in gliomas
por: Ebrahimi, Azadeh, et al.
Publicado: (2016)

The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas
por: Grandin, Nathalie, et al.
Publicado: (2019)

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas
por: Leeper, Heather E., et al.
Publicado: (2015)

Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss
por: Li, Xia, et al.
Publicado: (2017)

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
por: Jiao, Yuchen, et al.
Publicado: (2012)

Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas
por: Cai, Jinquan, et al.
Publicado: (2016)

Inhibition of p53 and ATRX increases telomeric recombination in primary fibroblasts
por: Udroiu, Ion, et al.
Publicado: (2023)

Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma
por: Nam, Yoonhee, et al.
Publicado: (2023)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

DAXX-ATRX regulation of p53 chromatin binding and DNA damage response
por: Gulve, Nitish, et al.
Publicado: (2022)

BRAF (AMP) Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAF (V600E)
por: Da, Rong, et al.
Publicado: (2021)

ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors
por: Cai, Jinquan, et al.
Publicado: (2016)

Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
por: Liu, Elisa K, et al.
Publicado: (2022)

Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies
por: Oppel, Felix, et al.
Publicado: (2019)

Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas
por: Park, Chul-Kee, et al.
Publicado: (2015)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

Long-term survivors of glioblastoma are a unique group of patients lacking universal characteristic features
por: Park, Chul-Kee, et al.
Publicado: (2019)

IDH1, ATRX, and BRAFV600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population
por: Chatterjee, Debajyoti, et al.
Publicado: (2018)

Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres
por: Yoon, Seon-Jin, et al.
Publicado: (2020)

Radiogenomics Profiling for Glioblastoma-related Immune Cells Reveals CD49d Expression Correlation with MRI parameters and Prognosis
por: Cho, Hye Rim, et al.
Publicado: (2018)

Magnetic resonance spectroscopic correlates of progression free and overall survival in “glioblastoma, IDH-wildtype, WHO grade-4”
por: Sacli-Bilmez, Banu, et al.
Publicado: (2023)

Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma
por: Akter, Jesmin, et al.
Publicado: (2021)

Immunohistochemical Detection of p53 Expression in Patients with Preoperative Chemoradiation for Rectal Cancer: Association with Prognosis
por: Huh, Jung Wook, et al.
Publicado: (2015)

GEN-13 FIREWORK PATTERN OF CANCER GENESIS FOR GLIOBLASTOMA, IDH-WILDTYPE
por: Yoon, Seon-Jin, et al.
Publicado: (2019)

Immunohistochemical and SSCP analysis of p53 in malignant lymphomas.
por: Park, C. K., et al.
Publicado: (1998)

The NADP(+)-dependent IDH1 mutation and its relevance for glioblastoma patient survival
por: Van Noorden, Cornelis JF
Publicado: (2014)

IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients
por: Amelot, Aymeric, et al.
Publicado: (2015)

Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival
por: Wang, Peng-Fei, et al.
Publicado: (2017)

The expression and significance of IDH1 and p53 in osteosarcoma
por: Hu, Xiang, et al.
Publicado: (2010)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
por: Haider, Ali S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mtiaca8ruljulg329vcg1l797s